2017, Number 6
PDF size: 389.04 Kb.
ABSTRACTNon-steroidal anti-inflammatory drugs are broad use drugs in the medical practice, their main adverse effects are gastrointestinal complications; however, in the last 10 years their cardiovascular safety has been questioned. The results from the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial challenged the cardiovascular safety of Cyclooxygenase-2 (COX 2) inhibitors. In this review, the results of the Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) trial are analysed, as well as their impact on the latest indications for this family of drugs.
Castelli G, Petrone A, Xiang J, Shrader C, King D. Rates of nonsteroidal anti-inflammatory drug use in patients with established cardiovascular disease: A retrospective, crosssectional study from NHANES 2009-2010. Am J Cardiovasc Drugs 2017 Jan 6. doi: 10.1007/s40256-016-0212-1. [Epub ahead of print].
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.